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Abstract 
Germline mutations in fundamental epigenetic regulatory molecules including DNA 
methyltransferase 3A (DNMT3A) are commonly associated with growth disorders, whereas 
somatic mutations are often associated with malignancy. We profiled genome-wide DNA 
methylation patterns in DNMT3A c.2312G>A; p.(Arg771Gln) carriers in a large Amish sibship 
with Tatton-Brown-Rahman syndrome (TBRS), their mosaic father and 15 TBRS patients with 
distinct pathogenic de novo DNMT3A variants. This defined widespread DNA hypomethylation 
at specific genomic sites enriched at locations annotated to genes involved in morphogenesis, 
development, differentiation, and malignancy predisposition pathways. TBRS patients also 
displayed highly accelerated DNA methylation aging. These findings were most marked in a 
carrier of the AML associated driver mutation p.Arg882Cys. Our studies additionally defined 
phenotype related accelerated and decelerated epigenetic aging in two histone 
methyltransferase disorders; NSD1 Sotos syndrome overgrowth disorder and KMT2D Kabuki 
syndrome growth impairment. Together, our findings provide fundamentally new insights into 
aberrant epigenetic mechanisms, the role of epigenetic machinery maintenance and 
determinants of biological aging in these growth disorders. 
 
 
 
 
 
 
  
 Cold Spring Harbor Laboratory Press on June 10, 2019 - Published by genome.cshlp.orgDownloaded from 
4 
 
Introduction  
DNA methylation is an essential epigenetic process involving the addition of a methyl group to 
cytosine. It is known to play a role in many important genomic regulatory processes, including X 
Chromosome inactivation, genomic imprinting and the repression of tumor suppressor genes in 
cancer, mediating transcriptional regulation as well as genomic stability (Jones 2012). Three 
catalytically active DNA methyltransferases (DNMTs) are involved in the methylation of 
cytosine: DNMT1, which is mainly responsible for the maintenance of DNA methylation over 
replication and DNMT3A and DNMT3B, which generally perform de novo methylation of either 
unmethylated or hemimethylated DNA. An absence of these enzymes in mice results in 
embryonic (DNMT1 and 3B) or postnatal (DNMT3A) lethality (Okano et al. 1999), confirming 
their essential roles in development. In line with knockout mouse models, pathogenic variants 
affecting the chromatin binding domains of DNMT1 have been shown to cause two separate 
progressive autosomal dominant adult-onset neurologic disorders (Klein et al. 2011). Biallelic 
pathogenic variants in DNMT3B have been associated with immunodeficiency, centromere 
instability and facial anomalies (ICF) syndrome (Jiang et al. 2005). To date, DNMT3A has been 
linked to a number of physiological functions, including cellular differentiation, malignant 
disease, cardiac disease, learning and memory formation. Somatically acquired pathogenic 
variants in DNMT3A are associated with over 20% of acute myeloid leukemia (AML) cases, 
whilst heterozygous germline pathogenic loss of function variants have been found to underlie 
Tatton-Brown-Rahman syndrome (TBRS; also known as DNMT3A-overgrowth syndrome, 
OMIM: 615879) (Challen et al. 2011; Tatton-Brown et al. 2014). TBRS is characterized by 
increased growth, intellectual disability (ID) and dysmorphic facial features. More recently, 
heterozygous gain of function DNMT3A missense variants affecting the DNMT3A PWWP 
domain have been shown to cause microcephalic dwarfism and hypermethylation of Polycomb-
regulated regions (Heyn et al. 2019). 
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There is an emerging group of epigenetic regulatory molecule-associated human growth 
disorders where the underlying molecular defect is a disruption to the DNA methylation and 
histone machinery. There are now over 40 disorders identified within this group, which can be 
further subgrouped into diseases resulting from disruption of the ‘writers’, ‘readers’ and ‘erasers’ 
of epigenetic modifications (Bjornsson 2015). Example disorders in each group include Kabuki, 
Sotos and Weaver syndromes (‘writers’), Smith-Magenis, Rett and Bohring-Optiz syndromes 
(‘readers’), and Wilson-Turner and Cleas-Hensen syndromes (‘erasers’). The final subgroup 
occurs due to disruption of chromatin remodellers, with example resulting disorders including 
CHARGE and Floating Harbour syndromes. Neurological and cognitive impairment are common 
features of these conditions, suggesting that precise epigenetic regulation may be critical for 
neuronal homeostasis.  However, a true understanding of the pathogenic mechanism underlying 
these conditions remains poorly understood.  
In the current study, we investigated the methylomic consequences of a DNMT3A pathogenic 
variant (NC_000002.12:g.25240312C>T; NM_022552.4:c.2312G>A; p.Arg771Gln) in a large 
Amish family comprising four individuals affected with TBRS arising due to a mosaic pathogenic 
DNMT3A variant in their father (Xin et al. 2017). The occurrence of multiple affected and 
unaffected individuals in the same sibship, together with the combined genetic and 
environmental homogeneity of the Amish, permitted an in-depth investigation of the genome-
wide patterns of DNA methylation associated with pathogenic variation in DNMT3A. We 
subsequently extended our analyses to other (non-Amish) TBRS patients harbouring distinct 
pathogenic de novo DNMT3A variants, as well other methyltransferase associated overgrowth 
and growth deficiency syndromes, defining altered epigenetic profiles as common key themes of 
these growth disorders. 
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Results 
Reduced DNA methylation at key sites involved in morphogenesis, development and 
differentiation in TBRS patients 
DNMT3A encodes a DNA methyltransferase with both de novo and maintenance activity 
(Okano et al. 1999; Chen et al. 2003). We first looked for global changes in DNA methylation in 
whole blood obtained from DNMT3A c.2312G>A; p.(Arg771Gln) carriers, using the methylation-
sensitive restriction enzyme based LUMA assay (Karimi et al. 2006) to quantify DNA 
methylation across GC rich regions of the genome, finding no evidence for altered global DNA 
methylation (LUMA: mean DNMT3A c.2312G>A carriers = 0.274, wildtype = 0.256, t-test p-
value = 0.728). We next quantified DNA methylation at 414,172 autosomal sites across the 
genome using the Illumina 450k array. Globally, a subtle decrease in mean DNA methylation 
was noted in available age/sex matched DNMT3A heterozygous c.2312G>A; p.(Arg771Gln) 
individuals compared to their matched unaffected sib samples although this was not statistically 
significant (Wilcoxon Rank Sum test p-values for two matched pairs=0.24 and 0.14, 
Supplemental Fig S1). In contrast, an analysis of site-specific DNA methylation differences in 
DNMT3A c.2312G>A; p.(Arg771Gln) carriers  (including the mosaic father) vs wildtype 
individuals in the Amish pedigree identified 2,606 differentially methylated positions (DMPs) 
(Benjamini-Hochberg FDR < 0.05) (Fig. 1A,B and Supplemental Table S1), of which 1,776 
DMPs were characterized by a >10% change in DNA methylation. Supplemental Fig S2 also 
highlights DNA methylation levels at these DMPs across all carriers and control individuals 
profiled in this study. Technical validation of Illumina 450K array data was performed using 
bisulfite pyrosequencing for three top-ranking DMPs, confirming significant differences in 
DNMT3A c.2312G>A carriers at each of the tested loci (Supplemental Fig S3).  
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The DMPs identified were highly enriched for sites characterized by reduced DNA methylation 
in DNMT3A c.2312G>A; p.(Arg771Gln) heterozygotes (n = 2,576 DMPs, 98.85%, sign-test p-
value < 2.2×10-16). Although there were no statistically significant differences between DNA 
methylation based blood cell composition estimates derived from our data (Supplemental Table 
S2), we examined the extent to which the identified DMPs were potentially influenced by cell-
type differences between DNMT3A c.2312G>A; p.(Arg771Gln) carriers and wildtype family 
members. There was a highly significant correlation (r = 0.876, p-value < 2.2×10-16, 
Supplemental Fig S4) in effect sizes at the 2,606 DMPs between models including and 
excluding cell-types as covariates, indicating that the observed patterns of differential DNA 
methylation are not strongly influenced by cell-type variation. We used DMRcate (Peters et al. 
2015) to identify spatially correlated regions of differential DNA methylation significantly 
associated with the DNMT3A c.2312G>A; p.(Arg771Gln) variant, identifying 388 autosomal 
differentially methylated regions (DMRs) (example DMR shown in Supplemental Fig S5), all 
characterized by hypomethylation in DNMT3A c.2312G>A; p.(Arg771Gln) carriers apart from 
one 739bp DMR which showed increased DNA methylation (Supplemental Table S3). The 
mean size of the identified DMRs was 625bp (range = 6 to 5,522bp), spanning an average of 6 
probes (Supplemental Fig S6).  
We next investigated whether DNMT3A p.(Arg771Gln)-associated DMPs are enriched in 
specific genic locations (see Methods). We found a modest enrichment of DMPs in regions 
1500bp or more upstream of the transcriptional start site (Chi-Squared Yates corrected p-
value=0.047) and more prominent enrichment in intergenic regions (Chi-Squared Yates 
corrected p-value=1.54×10-14) (Supplemental Fig S7). DMPs were also significantly enriched in 
CpG Island shore regions (Chi-Squared Yates corrected p-value=8×10-30) (Supplemental Fig 
S7). We also examined DMP occurrence in experimentally determined cancer and 
reprogramming specific DMR locations (Doi et al. 2009), finding a 2.4 fold and 4.7 fold 
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overrepresentation (Chi-Squared Yates corrected p-value=4.24×10-6 and Chi-Squared Yates 
corrected p-value<1.3×10-41 respectively), as well as predicted enhancer elements which 
showed a 1.4 fold overrepresentation (Chi-Squared Yates corrected p-value=7.57×10-16). We 
then undertook Gene Ontology analysis, accounting for the background distribution of probes on 
the Illumina 450K array, to functionally annotate the DNA methylation differences observed in 
the DNMT3A c.2312G>A; p.(Arg771Gln) carriers. The 2,606 DMPs identified in this study 
showed a significant overrepresentation in functional pathways related to morphogenesis, 
development and differentiation (top hit: GO:0007275 - multicellular organism development, 
contains 474 genes associated with DMPs, FDR Q-value=3.7×10-7) (Fig. 1C, Supplemental 
Table S4). We also performed a functional overlap analysis to identify cell- or tissue-specific 
chromatin signals associated with these DMPs using eFORGE (Breeze et al. 2016). Significant 
overlap (FDR Q-value < 0.01) was found with DNase I sensitivity hotspots, most apparent with 
pluripotent cells in ENCODE (The Encode Project Consortium 2012; Davis et al. 2018) and fetal 
tissues within the NIH Roadmap Epigenomics Consortium dataset (Roadmap Epigenomics 
Consortium 2015) (Supplemental Data S1). Chromatin states from the NIH Roadmap 
Epigenomics Consortium dataset show an enrichment of DMPs in regions defined as active 
transcriptional start sites in brain tissue and embryonic stem cells. Of particular interest, given 
the established importance of DNMT3A during embryonic development, eFORGE analysis of 
blood cell types highlighted an enrichment of DMPs in regions characterized by repressed 
polycomb and enhancer activity. 
To provide additional evidence to support the notion that DNMT3A c.2312G>A; p.(Arg771Gln) 
carriers exhibit disruption to developmental pathways, we used the Genomic Regions 
Enrichment of Annotation Tool (GREAT) (McLean et al. 2010) to explore functional pathways 
enriched in genes annotated to DNMT3A c.2312G>A; p.(Arg771Gln)-associated DMRs. This 
revealed a significant effect on genes implicated in developmental pathways (1st ranked GO 
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Biological Process = Skeletal System Development, fold enrichment = 2.5, binomial FDR Q-
value=9.22×10-7), with a specific enrichment for Homeobox protein domain encoding genes 
(InterPro) (fold enrichment=239.59, binomial FDR Q-value=4.15×10-23), fundamental for normal 
developmental processes. An enrichment for malignancy terms was also noted, (from the 
Molecular Signatures Database (Liberzon et al. 2011)) (1st ranked term = Genes with promoters 
occupied by PML-RARA fusion protein in acute promyelocytic leukemia (APL) cells NB4 and 
two APL primary blasts, based on ChIP-seq data, fold enrichment=3.14, binomial FDR Q-
value=6.18×10-7) (see Supplemental Data S2).  
To establish whether these differentially methylated positions are a consistent feature of TBRS, 
we profiled a further 15 non-Amish patients carrying distinct previously published DNMT3A 
pathogenic variants (Fig. 2 and Table 1) using the Illumina EPIC DNA methylation array. 
Examination of the originally differentially methylated positions identified in DNMT3A 
c.2312G>A; p.(Arg771Gln) mutation carriers revealed that the majority of differentially 
methylated positions were common to all of the TBRS patients regardless of the underlying 
causative DNMT3A variant (Fig. 1D), with a Pearson correlation coefficient of 0.6620 (p-
value<2.2×10-16) for effect sizes across all DMPs. Each variant showed some heterogeneity in 
effect size (Fig. 1E), with DNMT3A c.2644C>T p.(Arg882Cys) associated with the greatest 
overall changes in DNA methylation. These data lead us to conclude that TBRS patients show 
loss of methylation at sites annotated to key genes involved in development and growth 
pathways, mirroring the well-characterized overgrowth and neurocognitive features that 
characterize this disorder. 
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DNMT3A mutations are associated with highly accelerated epigenetic aging, particularly the 
cardinal AML driver mutation p.Arg882Cys 
DNA methylation at a specific set of CpG sites, representing a so-called “epigenetic clock”, has 
been shown to be strongly correlated with chronological age (Horvath 2013). Deviations from 
chronological age have been associated with several measures of accelerated biological aging 
and age-related phenotypes (Johnson et al. 2012; Levine et al. 2015; Marioni et al. 2015; Chen 
et al. 2016).  We investigated the DNA methylation age of DNMT3A c.2312G>A p.(Arg771Gln) 
carriers using the DNA age calculator (http://dnamage.genetics.ucla.edu/) (Horvath 2013) 
finding that DNMT3A c.2312G>A; p.(Arg771Gln) carriers show evidence for highly-accelerated 
aging - an increase of ~40% beyond their chronological age - when compared to wildtype family 
members (ANCOVA p-value=0.004) (Fig. 3A). Only 1 of 353 probes used in the epigenetic clock 
(Horvath 2013) overlapped with the DMPs significantly associated with the DNMT3A 
c.2312G>A; p.(Arg771Gln) pathogenic variant, leading us to conclude that this finding 
represented a true acceleration of epigenetic age. Furthermore, when compared to an extensive 
number (322) of wild-type control samples profiled in a previous study from our group (Hannon 
et al. 2016), DNMT3A c.2312G>A; p.(Arg771Gln) carriers were consistent outliers for epigenetic 
age suggesting their profiles fall outside the normal distribution of variance observed in the 
general population (Supplemental Fig S8). Consistent with this, the mosaic Amish father was 
found to have intermediate level of epigenetic age acceleration, with a 23% increase over his 
chronological age. This age acceleration was a cumulative process as indicated by the 
increased slope of DNMT3A c.2312G>A; p.(Arg771Gln) carriers vs wildtype. Epigenetic age 
could therefore be predicted by the linear regression model as follows: epigenetic age = 4.81 + 
1.405 × chronological age. The cumulative increase of epigenetic age relative to chronological 
age is also notable when compared to a recent meta-analysis of longitudinal cohort data which 
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shows the trajectory of epigenetic age in different populations progresses at a slightly slower 
rate when compared to increasing chronological age (Marioni et al. 2018). 
We next looked for evidence of elevated epigenetic aging in the 15 additional de novo DNMT3A 
pathogenic variant carriers with TBRS overgrowth syndrome. All TBRS patients showed 
accelerated epigenetic aging, although the position and type of each variant results in differing 
degrees of accelerated epigenetic aging (Table 1). The greatest rate of epigenetic age 
acceleration (>800%) was observed in association with the germline p.(Arg882Cys) substitution, 
somatic mutation of DNMT3A Arg882 being the most commonly associated with acute myeloid 
leukemia (AML).   
 
Altered epigenetic aging in methyltransferase-associated human growth disorders  
To determine whether altered epigenetic aging is a characteristic of other growth disorders 
associated with disruption of epigenetic regulatory molecules, we extended our study using 
publicly-available Illumina 450K DNA methylation data. We first analysed the data from 
individuals with Sotos syndrome, a congenital overgrowth syndrome which results from mutation 
of the epigenetic modifier NSD1 (Supplemental Table S5), a lysine histone methyltransferase, 
(Kurotaki et al. 2002; Qiao et al. 2011). Consistent with DNMT3A pathogenic variant carriers, 
these individuals are characterized by an epigenetic age acceleration of ~40% (linear 
regression model R2=0.869, p-value=6.4×10-9) (Fig. 3B,3D). We then examined data from 
individuals with Kabuki syndrome patients with pathogenic variants in the KMT2D gene 
(Supplemental Table S6), which also encodes a lysine histone methyltransferase, (Ng et al. 
2010; Butcher et al. 2017). Kabuki syndrome is a multisystem disorder with patients typically 
presenting with post-natal growth deficiency (rather than overgrowth), characteristic facial 
features, intellectual disability and other variable features. Although there is more heterogeneity 
in epigenetic age when compared with the NSD1 mutation carriers there was a significant 
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reduction in epigenetic age of approximately 40% seen across these individuals (linear 
regression model R2=0.418, p-value=0.023) (Fig. 3C,3D).  
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Discussion 
To date, 78 individuals have been described with the overgrowth condition TBRS. Within this 
group a wide variety of germline DNMT3A pathogenic variants have been reported including 33 
missense, eight stop-gain, seven frameshift, two splice site variants, two in-frame and five 
whole-gene deletions (including a set of identical twins) (Tatton-Brown et al. 2014; Okamoto et 
al. 2016; Tlemsani et al. 2016; Hollink et al. 2017; Kosaki et al. 2017; Lemire et al. 2017; Shen 
et al. 2017; Spencer et al. 2017; Tatton-Brown et al. 2017; Xin et al. 2017; Tatton-Brown et al. 
2018). Clinically, the predominant features of TBRS are overgrowth, a characteristic facial 
gestalt and neurocognitive impairment. These features show phenotypic overlap with conditions 
associated with germline pathogenic variants in other epigenetic regulatory genes, including 
Sotos and Weaver syndrome caused by variants in NSD1 and EZH2 histone methyltransferases 
respectively (Tatton-Brown et al. 2017). These genes encode essential epigenetic regulatory 
proteins, with a dual somatic/germline role in the pathogenesis of haematological malignancies 
and overgrowth syndromes with variable degrees of intellectual impairment (Tatton-Brown et al. 
2014).  
The majority of DNMT3A pathogenic variants in TBRS have been found to be de novo, with five 
individuals inheriting the pathogenic variant from two mosaic parents (Tlemsani et al. 2016; Xin 
et al. 2017) and two individuals inheriting the pathogenic variant from their affected father 
(Lemire et al. 2017). Extensive studies of the role of DNMT3A in haematopoietic stem cell 
(HSC) differentiation are also reported, including the regular occurrence of somatic DNMT3A 
variants in patients with acute myeloid leukaemia (AML). The most common somatic pathogenic 
variant reported in patients with AML affects the amino acid residue Arg882. To date, 
pathogenic variation at this residue has been described in the germline of 12 TBRS patients, 
five with p.(Arg882His) and seven with p.(Arg882Cys) (Tlemsani et al. 2016; Hollink et al. 2017; 
Kosaki et al. 2017; Shen et al. 2017; Spencer et al. 2017; Tatton-Brown et al. 2018). Despite 
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these studies, the underlying biological mechanism and outcomes of gene mutation in TBRS, 
and the potential risks of haematological malignancy, remain largely unclear.  
Here we investigated variation in DNA methylation associated with a germline heterozygous 
DNMT3A missense pathogenic variant c.2312G>A; p.(Arg771Gln), affecting the catalytic MTase 
domain, in a large Amish family comprising four children with TBRS, unaffected siblings, and 
their mosaic father who displayed an intermediate clinical phenotype (Xin et al. 2017). Affected 
individuals were characterized by widespread hypomethylation, with DMPs enriched in the 
vicinity of genes/regulatory regions associated with growth and development, tissue 
morphogenesis and differentiation. The magnitude of hypomethylation typically exceeded 10%, 
a level often considered to show biological significance (Leenen et al. 2016).  The accelerated 
epigenetic age observed did not appear to be driven by overlap of the DNMT3A c.2312G>A; 
p.(Arg771Gln) variant associated DMPs with the probes that comprise the epigenetic clock as 
shown by overlap with only 1 out of the 353 probes used in the epigenetic age estimation 
(Horvath 2013). Although the relevance of blood cells to understanding the aetiology of TBRS is 
not yet known, we hypothesize that our findings will be generalizable across cell types given the 
ubiquitous developmental expression of DNMT3A and given that many age associated 
differentially methylated positions are shared across different cell types (Zhu et al. 2018). 
Nevertheless, it would still be prudent to undertake epigenetic age assessment of other tissues 
from TBRS patients to determine whether epigenetic age truly is accelerated across all cell 
types or a finding that is limited to blood.  
While dysregulation of growth control has been linked to numerous developmental disorders 
and malignancy, the specific molecular basis of this relationship is not fully understood. The 
assessment of DMPs associated with DNMT3A c.2312G>A; p.(Arg771Gln) variant TBRS 
individuals showed associations of pluripotent and fetal DNase I sensitivity hotspots, and also 
brain and embryonic stem cell associated chromatin sites according to The Encode Project 
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Consortium and Epigenomic Roadmap Consortium datasets (Breeze et al. 2016). Similarly, 
functional annotation based on Gene Ontology terms showed an overrepresentation 
morphogenesis, development and differentiation. DNMT3A loss of function has previously been 
reported to result in upregulated multipotency genes and impaired differentiation of neural and 
hematopoietic stem cells (Wu et al. 2010; Challen et al. 2011; Jeong et al. 2018) compared to a 
gain of function DNMT3A variant which may increase cellular differentiation (Heyn et al. 2019). 
It is therefore conceivable that the DNMT3A loss of function variants associated TBRS may 
promote increased proliferation of stem/progenitor cell pool, resulting in increased cell numbers 
during organ morphogenesis and clinical overgrowth.  
Our finding of altered epigenetic outcomes in TBRS prompted us to consider similar 
investigations in other growth disorders associated with epigenetic dysfunction; Sotos 
syndrome, a neurodevelopmental disorder with features overlapping TBRS and associated with 
overgrowth in childhood due to histone methyltransferase NSD1 gene alterations, and Kabuki 
syndrome, a distinct neurodevelopmental disorder associated with poor growth and histone 
methyltransferase KMT2D gene alterations. This work defined clear aberrations in epigenetic 
aging appropriate to the specific nature of each condition. In both overgrowth conditions, TBRS 
and Sotos syndrome, we identified accelerated epigenetic aging as measured by the DNA 
methylation age calculator (Horvath 2013). Conversely patients with Kabuki syndrome clinically 
characterized by poor growth, displayed decelerated epigenetic age. Epigenetic age has 
been strongly correlated with chronological age in unaffected individuals in previous studies of a 
variety of tissue types (Hannum et al. 2013; Horvath 2013). The observation of accelerated 
epigenetic aging in both TBRS and Sotos syndrome potentially results from reduced 
methyltransferase activity, in addition to increased cell turnover associated with the overgrowth 
seen with these disorders, with the converse being the case for Kabuki syndrome. Accelerated 
epigenetic aging has been associated with age-related clinical characteristics and mortality in 
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epidemiological studies. For example, accelerated epigenetic age in lymphocytes correlates 
with reduced physical and cognitive function in the elderly, and increased overall mortality 
independent of other variables such as BMI, sex and smoking status (Marioni et al. 2015; Chen 
et al. 2016).  The molecular basis of TBRS has only been determined relatively recently and as 
such, most of the affected individuals reported are children and young adults. There is therefore 
still only very limited data available relating to the progression and prognosis of this disorder, 
meaning that it is not yet possible to determine whether there might any clinical evidence of 
multi-morbidity indicative of premature aging or a reduction in average life span in TBRS. 
Further long-term natural history studies of TBRS patients will be extremely helpful for 
determining the clinical implications of the epigenetic age acceleration observed as a feature of 
this disorder.  
Accelerated epigenetic age has previously been reported in association with specific diseases 
such as Huntington’s disease (+ 3.4 years) (Horvath et al. 2016), Down’s syndrome (+ 6.6 
years) (Horvath et al. 2015) and Werner’s syndrome (+ 6.4 years) (Maierhofer et al. 2017). The 
accelerated epigenetic aging described in association with these disorders is an average 
increase in epigenetic age which is relatively consistent throughout lifespan. A distinguishing 
feature of carriers of the Amish DNMT3A c.2312G>A; p.(Arg771Gln) variant is the year on year 
or cumulative increase of accelerated epigenetic aging over life time course, i.e. a true 
acceleration of epigenetic aging. While these studies were not possible for the other DNMT3A 
variants, this may be indicative of a similar effect on cumulative epigenetic age acceleration 
over life course in TBRS. It is also noted that the gene encoding DNMT3L is located on 
Chromosome 21, given the previous report of an average DNA methylation age acceleration of 
6.6 years in blood and brain tissue in individuals with Down syndrome (Horvath et al. 2015) and 
the role of DNMT3L in stimulating DNMT3A de novo methylation, further investigations are 
needed to explore the potential relevance of this intriguing observation.  
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There are currently only four reported cases of an AML tumour carrying the DNMT3A 
p.Arg771Gln mutation which was present as a germline mutation in the Amish TBRS patients in 
our study. Biochemical measurements of DNMT3A enzyme show that mutations at both the 
Arg771 and Arg882 residues result in reduced methyltransferase activity, with a greater degree 
of reduction resulting from Arg882 variants compared to Arg771 variants (2.4 fold difference) 
(Holz-Schietinger et al. 2012). Given this reduced methyltransferase activity, we may expect to 
observe more pronounced changes in DNA methylation in patients with germline variants 
affecting Arg882 when compared to variants affecting other amino acid residues such as 
Arg771. Our data reflected this notion, with alteration Arg882 displaying markedly greater 
methylation changes compared to the other DNMT3A mutations investigated in this study. 
Currently available literature suggests that the risk of haematological malignancy in TBRS 
individuals may vary depending on the specific pathogenic variant underling their condition 
(Hollink et al. 2017).  The significantly advanced epigenetic age that we observed in association 
with p.Arg882Cys may explain why haematological malignancy has to date only been reported 
in two TBRS patients, one harbouring this germline variant and the second the p.Tye735Ser 
variant, the latter not being assessed in this study (Hollink et al. 2017; Tatton-Brown et al. 
2018).  
In summary, our findings identify widespread DNA hypomethylation in genes involved in 
morphogenesis, development, differentiation and malignancy in TBRS patients. TBRS patients 
also displayed highly accelerated DNA methylation aging. Our studies additionally defined 
phenotype related altered epigenetic aging in two histone methyltransferase disorders; NSD1 
Sotos syndrome overgrowth disorder and KMT2D Kabuki syndrome growth impairment. Taken 
together, these findings provide important new insights into the role of DNMT3A during 
development, and of relevance to haematological malignancy, and define perturbation to 
 Cold Spring Harbor Laboratory Press on June 10, 2019 - Published by genome.cshlp.orgDownloaded from 
18 
 
epigenetic machinery and biological ageing as common themes in overgrowth and growth 
deficiency syndromes.  
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Methods 
Genetic and Clinical Studies 
The phenotypic features of the four affected siblings (3 females and 1 male, aged 10-25 years; 
Fig. 1A individuals III:3, III:5, III:7 and III:13) include: macrocephaly, tall stature, obesity, 
hypotonia, mild to moderate intellectual disability, behavioural problems, and a distinctive facial 
appearance. Whole genome SNP genotyping and exome sequencing of DNA samples taken 
with informed consent under regionally-approved protocols excluded mutations in known genes, 
or candidate new genes, associated with neurodevelopmental disorders. Subsequent studies 
defined a heterozygous c.2312G>A substitution in DNMT3A, resulting in a p.(Arg771Gln) 
substitution associated with TBRS as the cause of the condition, and full clinical details are 
described in Xin et al 2017 (Xin et al. 2017). Further testing revealed mosaicism for the 
DNMT3A c.2312G>A variant in the father, and Xin et al. (Xin et al. 2017), demonstrated 
pathogenic variant load varied in different tissue types.  
 
DNA Methylation Profiling  
Genomic DNA from blood was sodium bisulfite converted using the EZ-96 DNA Methylation Kit 
(Zymo Research, Irvine, CA, USA) and DNA methylation quantified across the genome using 
the Illumina Infinium HumanMethylation450 array (“Illumina 450K array”) (Illumina, San Diego, 
CA, USA). The additional 15 DNMT3A pathogenic variants were profiled using the Illumina 
Infinium EPIC array (Illumina, San Diego, CA, USA). The Bioconductor package wateRmelon 
(Pidsley et al. 2013) in R 3.4.1 (R Core Team 2017) was used to import IDAT files and, after 
checking for suitable sodium bisulfite conversion (bisulfite control probe median > 90%), the 
DNA methylation data was imported and quantile normalized using the dasen function in 
wateRmelon and methylation beta values produced (ratio of intensities for methylated vs 
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unmethylated alleles). Probes showing a detection p-value >0.05 in at least 1% of samples or a 
beadcount <3 in 5% of samples were removed across all samples. Any samples showing low 
quality, indicated by a detection p-value > 0.05 in 1% or more of probes within a sample, were 
removed from analysis. Probes containing common SNPs within 10 bp of the CpG site were 
removed (minor allele frequency > 5%). Nonspecific probes and probes on the sex 
chromosomes were also removed (Chen et al. 2013; Price et al. 2013).  
 
Identification of Differentially Methylated Positions 
Differentially methylated positions (DMPs) were identified using a limma based linear model 
based on pathogenic variant genotype and sex as a covariate (Smyth 2004) and a Benjamini-
Hochberg false discovery rate (FDR) of 5% applied (Benjamini and Hochberg 1995). When the 
epigenetic age was used as a covariate, a similar level of DMPs were detected (2,557 DMPs) 
with an 80% overlap to the limma model without age as a covariate. Changes in methylation 
were calculated based on comparison between DNMT3A c.2312G>A; p.(Arg771Gln) carriers vs 
wildtype individuals in the Amish pedigree. The additional 15 DNMT3A pathogenic variants were 
assessed relative to 7 wild-type control samples run on the same EPIC array run. Blood cell 
counts were unknown and so were estimated using the DNA methylation age calculator 
(Horvath 2013; Koestler et al. 2013), and assessed in the linear model. To identify differentially 
methylated regions (DMRs), the package DMRcate was used with the same limma based 
design (Peters et al. 2015).  
 
Gene Ontology and Functional Enrichment Analyses 
Gene Ontology enrichment analysis was performed using genes annotated to FDR corrected 
differentially methylated positions using the gometh function of the missMethyl package 
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(Phipson et al. 2016) which takes into account potential bias of probe distributions on the 
beadchip array. KEGG pathway analysis was performed using the gsameth command of 
missMethyl and KEGG annotation files from the Bioconductor KEGGREST package 
(http://bioconductor.org/packages/release/bioc/html/KEGGREST.html). Regional enrichment 
analysis based on Illumina annotations was performed using a Chi-squared test with Yates 
correction in R. Differentially methylated regions were functionally annotated using the webtool 
GREAT (http://great.stanford.edu/public/html/). The top p-value ranked 1,000 DMPs were also 
annotated using the eFORGE tool (https://eforge.altiusinstitute.org/) to perform functional 
overlap analysis for identifying any cell or tissue specific epigenetic signals. 
 
Quantification of Global DNA Methylation 
Global DNA methylation measurements were made using the Luminometric methylation assay 
(LUMA) (Karimi et al. 2006) based on cleavage by a methylation sensitive restriction enzyme 
followed by polymerase extension assay via pyrosequencing on the Pyromark Q24 (Qiagen). 
Peak heights were obtained using the Pyro Q24 CpG 2.0.6 software and a t-test applied in R 
3.4.1. Global methylation estimates from the Illumina 450k array were assessed through R 3.4.1 
using summary statistics and a Wilcoxon rank sum test on two pairs of samples matched for 
age and sex.  
 
DNA Methylation Age Estimation 
Epigenetic age calculations were made using the DNA methylation age calculator 
(https://dnamage.genetics.ucla.edu/) for Illumina 450k data, and Illumina EPIC arrays assessed 
using the agep function of the wateRmelon Bioconductor package, the latter based on the 
original calculator developed by Steve Horvath (Horvath 2013). Accelerated age was calculated 
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for the Amish TBRS DNMT3A c.2312G>A; p.(Arg771Gln) carriers and wildtype family members, 
Sotos syndrome and Kabuki syndrome patients, and compared to data from 322 control 
individuals taken from a previous study (Hannon et al. 2016), using linear models of recorded 
chronological age and calculated epigenetic age. Estimates of age acceleration for the 
additional 15 TBRS cases were calculated by dividing the calculated epigenetic age with their 
chronological age. Additional NSD1 Sotos syndrome patient Illumina DNA methylation files were 
obtained from GEO accession GSE74432, with corresponding chronological ages derived from 
the associated paper (Choufani et al. 2015). KMT2D Kabuki syndrome DNA methylation data 
and chronological age was obtained from GEO accession GSE97362 (Butcher et al. 2017).  
 
Validation of DMPs using Bisulfite-Pyrosequencing 
Bisulfite pyrosequencing was used to validate specific differentially methylated CpG sites 
originally identified using the Illumina 450k array. Primers, designed using Pyromark Assay 
Design software (Qiagen, UK), and PCR conditions are provide in Table S7. Bisulfite conversion 
DNA was performed on ~500ng of DNA using the Bisulfite-Gold kit (Zymo Research, USA). 
PCR was performed with HOT FIREPol DNA polymerase (Solis Biodyne, Estonia) for 95°C for 
15 minutes followed by 37 cycles of 95°C 15 seconds, annealing temperature (shown in 
Supplemental Table S7) for 15 seconds and 72°C for 30 seconds. A final extension of 72°C for 
10 minutes was then applied. DNA methylation was then assessed using the resulting bisulfite 
PCR amplicons, together with a pyrosequencing primer on the Pyromark Q24 system (Qiagen, 
UK) following the manufacturer's standard instructions and the Pyro Q24 CpG 2.0.6 software.  
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Data Access 
The raw and processed primary dataset generated in this study have been submitted to the 
NCBI Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession 
number GSE128801. R scripts are provided as Supplemental Code S1 and at the following 
repository: https://github.com/arjeffries/TBRS2019. 
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Figure Legends 
 
Figure 1 – TBRS DNMT3A variants are associated with widespread DNA hypomethylation 
(A) Simplified pedigree indicating the genotyping of individuals in the Amish family investigated 
(‘+/-‘; heterozygous carriers of the DNMT3A c.2312G>A p.(Arg771Gln) variant, ‘+/- Mosaic’; the 
DNMT3A c.2312G>A p.(Arg771Gln) mosaic father, and ‘-/-‘; wildtype individuals). Black 
shading; individuals with a phenotype consistent with TBRS, grey shading; the father with 
macrocephaly and mild intellectual impairment, and white shading; unaffected individuals. Each 
of these samples was profiled on the Illumina 450k DNA methylation array. 
(B) Volcano plot showing site-specific DNA methylation differences (x-axis) and –log10 P values 
(y-axis) from an analysis comparing Amish DNMT3A c.2312G>A; p.(Arg771Gln) pathogenic 
variant carriers and wildtype family members using the Illumina 450K array. Red values indicate 
the 2,606 differentially methylated positions (DMPs) detected at a Benjamini Hochberg FDR < 
0.05. 
(C) Top 20 Gene Ontology enrichment analysis categories associated with the 2,606 
differentially methylated positions identified in DNMT3A c.2312G>A; p.(Arg771Gln) pathogenic 
variant carriers vs wildtype family members. 
(D) Comparison of DNMT3A c.2312G>A; p.(Arg771Gln) identified differentially methylated 
positions (log2 fold change) relative to other DNMT3A TBRS associated variants assessed in 
this study (all variants grouped and measured relative to controls). Pearson correlation = 
0.6620, p-value < 2.2 × 10-16.  
 (E) Boxplot illustrating the DNA methylation changes observed in association with the DNMT3A 
TBRS variants studied at the differentially methylated positions identified in the Amish DNMT3A 
c.2312G>A p.(Arg771Gln)carriers. The predicted protein consequence of each DNMT3A variant 
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studied is indicated (pink; in-frame deletion, yellow; single nucleotide variant, cyan; duplications 
predicted to result in a frameshift, green; Amish c.2312G>A; p.(Arg771Gln) variant). 
 
Figure 2 – Schematic representation of DNMT3A. 
The positions of the disease-associated variants included in this study are indicated relative to 
the protein domain architecture.  
 
Figure 3 – Altered epigenetic aging is observed in methyltransferase-associated human 
growth disorders. 
(A) Scatter plot comparing ‘DNA methylation age’ derived from the Illumina 450K data (y-axis) 
and actual chronological age (x-axis) in DNMT3A c.2312G>A p.(Arg771Gln) pathogenic variant 
carriers (red) vs wildtype family members (blue). Green indicates the mosaic individual. The 
linear regression model is also shown. 
(B) Scatter plot comparing DNA methylation age vs chronological age in patients with Sotos 
syndrome. Inframe legend illustrates the different NSD1 pathogenic variants studied.  
(C) Scatter plot comparing DNA methylation age vs chronological age in patients with Kabuki 
syndrome. Inframe legend illustrates the different KMT2D pathogenic variants studied.  
(D) Boxplot comparing the epigenetic age acceleration rates found in association with TBRS 
DNMT3A variants, KMT2D Kabuki syndrome variants and NSD1 Sotos syndrome variants. 
Each age acceleration observation is plotted as a circle. The dotted red line denotes no age 
acceleration.  
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 ID   Mutation (nucleotide) 
Mutation 
(protein) 
Chronological 
Age (years) 
Epigenetic 
Age 
(years) 
Epigenetic 
Age 
Acceleration 
(fold 
change) 
Epigenetic Age 
Acceleration 
(percentage 
increase) 
Single nucleotide variants 
1 c.929T>A p.(Ile310Asn) 9.27 24.2 2.61 161% 
2 c.1594G>A p.(Gly532Ser) 5.92 22.7 3.83 283% 
3 c.1645T>C p.(Cys549Arg) 9.36 25 2.67 167% 
4 c.1943T>C p.(Leu648Pro) 19.34 32.1 1.66 66% 
5 c.2099C>T p.(Pro700Leu) 13.45 32.5 2.42 142% 
6 c.2245C>T p.(Arg749Cys) 13.87 19.6 1.41 41% 
7 c.2246G>A p.(Arg749His) 8.9 33.6 3.78 278% 
8 c.2312G>A p.(Arg771Gln) 8 - 23 15.8 - 36.1 1.41 41%* 
9 c.2512A>G p.(Asn838Asp) 14.44 38.8 2.69 169% 
10 c.2644C>T p.(Arg882Cys) 2.28 21.9 9.61 861% 
11 c.2705T>C p.(Phe902Ser) 9.84 25.4 2.58 158% 
12 c.2711C>T p.(Pro904Leu) 7.78 35.7 4.59 359% 
In-frame deletions 
13 c.889_891delTGG p.(Trp297del) 5.82 23.2 3.99 299% 
14 c.2255_2257delTCT  p.(Phe752del) 3.05 10.6 3.48 248% 
Duplications resulting in a  frameshift 
15 c.2297dupA p.(Arg767fs) 3.12 14.4 4.62 362% 
16 c.934_937dupTCTT p.(Ser312fs) 21 38.9 1.85 85% 
 
Table 1 – TBRS DNMT3A variants are associated with epigenetic age acceleration. 
 DNMT3A genotype (p.(Arg771Gln), shown in blue; p.(Arg882Cys), shown in red), chronological 
age, predicted epigenetic age and percentage of age acceleration calculated for TBRS 
syndrome cases included in this study, * Epigenetic age acceleration taken from the linear 
regression model applied to 4 individuals carrying the mutation. 
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